RESUMO
MigriHeal®, is a novel herbal remedy that was introduced for the treatment of migraine headaches. Previous studies revealed that this drug may reduce nitric oxide (NO) in an in vitro inflammatory model. The aim of the present study was to investigate the antiinflammatory effect of MigriHeal® on primary mix glial cells stimulated with LPS. In the current study, neonatal rat primary mix glial cells were isolated from the mixed glial cultures via shaking, and cultured in Dulbecco's' modified Eagle's medium supplemented with 10% fetal bovine serum. Following pretreatment with MigriHeal® (25, 75, 100, 150, 200 and 300 µg/ml) and cells were treated with LPS (10 µg/ml) for 1 h, and incubated for 48 h. The present study determined that 150 µg/ml MigriHeal® signiï¬cantly reduced the production of NO in rat mix glial cells stimulated with 10 µg/ml LPS. MigriHeal® also suppressed mRNA expression level of LPSinduced inducible nitric oxide synthase and tumor necrosis factor α, which was accompanied by inhibition of the transcription factor nuclear factorκB. Additionally, MTT assay determined that MigriHeal® was not cytotoxic, suggesting that the antiinflammatory effects of MigriHeal® observed were not due to cell death. In conclusion, the findings of the present study demonstrated that MigriHeal® may be useful as a potential antiinflammatory agent in inflammatory diseases. However, additional studies are required to confirm these findings.